{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:51:20Z","timestamp":1793404280353,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment options for Exserohilum rostratum meningoencephalitis and other causes of phaeohyphomycosis of the central nervous system (CNS) are limited, while mortality and morbidity remain high. We therefore evaluated isavuconazole, a new antifungal triazole in comparison to liposomal amphotericin B (LAMB), in vitro and in the rabbit model of Exserohilum rostratum meningoencephalitis. We hypothesized that isavuconazole alone or in combination with LAMB or micafungin may be alternative options for treatment of CNS phaeohyphomycosis. We therefore investigated the in vitro antifungal activity of isavuconazole alone or in combination with amphotericin B deoxycholate (DAMB) or micafungin and efficacy of treatment with isavuconazole and LAMB in a rabbit model of experimental E. rostratum meningoencephalitis. Combination checkerboard plates were used to determine the minimum inhibitory concentrations, minimal lethal concentrations, fractional inhibitory concentration indices, and Bliss surface analysis of isavuconazole and amphotericin B deoxycholate (DAMB), either alone or in combination. As there were no in vitro synergistic or antagonistic interactions for either combination of antifungal agents against the E. rostratum isolates, in vivo studies were conducted with isavuconazole and LAMB as monotherapies. Rabbits were divided in following groups: treated with isavuconazole at 60 mg\/kg\/d (ISAV60), LAMB at 5.0 (LAMB5), 7.5 (LAMB7.5), and 10 mg\/kg\/d (LAMB10), and untreated controls (UC). In ISAV60-, LAMB5-, LAMB7.5-, and LAMB10-treated rabbits, significant reductions of fungal burden of E. rostratum in cerebral, cerebellar, and spinal cord tissues (P\u00a0&amp;lt;\u00a00.01) were demonstrated in comparison to those of UC. These antifungal effects correlated with significant reduction of CSF (1\u21923)-\u03b2-D-glucan levels vs UC (P\u00a0&amp;lt;\u00a00.05). These data establish new translational insights into treatment of CNS phaeohyphomycosis.<\/jats:p>","DOI":"10.1093\/mmy\/myaa102","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T20:50:45Z","timestamp":1607374245000},"page":"189-196","source":"Crossref","is-referenced-by-count":6,"title":["Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of <i>Exserohilum rostratum<\/i> meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis"],"prefix":"10.1093","volume":"59","author":[{"given":"Vidmantas","family":"Petraitis","sequence":"first","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Petraitiene","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Katragkou","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Bo Win","family":"Maung","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patriss W","family":"Moradi","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gittel E","family":"Sussman-Straus","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Naing","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L","family":"Kovanda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A","family":"Finkelman","sequence":"additional","affiliation":[{"name":"Associates of Cape Cod, Inc., East Falmouth, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Department of Microbiology & Immunology, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Department of Pediatrics, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"2021020323553600000_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","article-title":"Mold infections of the central nervous system","volume":"371","author":"McCarthy","year":"2014","journal-title":"N Engl J Med."},{"key":"2021020323553600000_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"2021020323553600000_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"2021020323553600000_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1086\/380635","article-title":"Primary central nervous system phaeohyphomycosis: a review of 101 cases","volume":"38","author":"Revankar","year":"2004","journal-title":"Clin Infect Dis."},{"key":"2021020323553600000_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/jof5030060","article-title":"CNS infections caused by brown-black fungi","volume":"5","author":"Velasco","year":"2019","journal-title":"J Fungi."},{"key":"2021020323553600000_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"2021020323553600000_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"2021020323553600000_bib8","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/AAC.01218-15","article-title":"In vitro activities of eight antifungal drugs against a global collection of genotyped Exserohilum isolates","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"2021020323553600000_bib9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/myc.12895","article-title":"In vitro susceptibility of dematiaceous fungi to nine antifungal agents determined by two different methods","volume":"62","author":"Zheng","year":"2019","journal-title":"Mycoses."},{"key":"2021020323553600000_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1017\/dmp.2015.137","article-title":"Clinical response, outbreak investigation, and epidemiology of the fungal meningitis epidemic in the United States: systematic review","volume":"10","author":"Abbas","year":"2016","journal-title":"Disaster Med Public Health Prep."},{"key":"2021020323553600000_bib11","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1056\/NEJMoa1304879","article-title":"Clinical findings for fungal infections caused by methylprednisolone injections","volume":"369","author":"Chiller","year":"2013","journal-title":"N Engl J Med."},{"key":"2021020323553600000_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clinmicnews.2013.11.001","article-title":"Exserohilum rostratum: anatomy of a national outbreak of fungal meningitis","volume":"35","author":"Larone","year":"2013","journal-title":"Clin Microbiol Newslett."},{"key":"2021020323553600000_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11908-014-0441-x","article-title":"Outbreak of fungal infections associated with contaminated methylprednisolone acetate: an update","volume":"17","author":"Pettit","year":"2015","journal-title":"Curr Infect Dis Rep."},{"key":"2021020323553600000_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid2303.161334","article-title":"Fungal contamination of methylprednisolone causing recurrent lumbosacral intradural abscess","volume":"23","author":"Renfrow","year":"2017","journal-title":"Emerg Infect Dis."},{"key":"2021020323553600000_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/JCM.03369-12","article-title":"A real-time PCR assay for rapid detection and quantification of Exserohilum rostratum, a causative pathogen of fungal meningitis associated with injection of contaminated methylprednisolone","volume":"51","author":"Zhao","year":"2013","journal-title":"J Clin Microbiol."},{"key":"2021020323553600000_bib16","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard - Second Edition. CLSI document M38-A2","author":"CLSI","year":"2008"},{"key":"2021020323553600000_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00305-17","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"2021020323553600000_bib18","volume-title":"In vitro interaction between isavuconazole and micafungin or amphotericin B against medically important moulds","author":"Petraitis","year":"2013"},{"key":"2021020323553600000_bib19","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1128\/AAC.00873-06","article-title":"Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model","volume":"51","author":"Meletiadis","year":"2007","journal-title":"AAC"},{"key":"2021020323553600000_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jof6010033","article-title":"Posaconazole alone and in combination with caspofungin for treatment of experimental Exserohilum rostratum meningoencephalitis: developing new strategies for treatment of phaeohyphomycosis of the central nervous system","volume":"6","author":"Petraitiene","year":"2020","journal-title":"J Fungi."},{"key":"2021020323553600000_bib21","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council","year":"2011","edition":"8th ed"},{"key":"2021020323553600000_bib22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/JCM.25.5.931-932.1987","article-title":"Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans","volume":"25","author":"Walsh","year":"1987","journal-title":"J Clin Microbiol."},{"key":"2021020323553600000_bib23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"57","author":"McCarthy","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"2021020323553600000_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"2021020323553600000_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis."},{"key":"2021020323553600000_bib26","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"2021020323553600000_bib27","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","author":"Petraitis","year":"2009","journal-title":"AAC."},{"key":"2021020323553600000_bib28","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin","volume":"187","author":"Petraitis","year":"2003","journal-title":"J Infect Dis."},{"key":"2021020323553600000_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med."},{"key":"2021020323553600000_bib30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1213978","article-title":"Fungal infections associated with contaminated methylprednisolone injections","volume":"369","author":"Smith","year":"2013","journal-title":"N Engl J Med."},{"key":"2021020323553600000_bib31","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1055\/s-0037-1598248","article-title":"Cladophialophora bantiana: a rare intracerebral fungal abscess-case series and review of literature","volume":"3","author":"Ahmad","year":"2017","journal-title":"Surg J."},{"key":"2021020323553600000_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/mmy\/myv091","article-title":"Brain abscess due to Cladophialophora bantiana: a review of 124 cases","volume":"54","author":"Chakrabarti","year":"2016","journal-title":"Med Myco."},{"key":"2021020323553600000_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/clinids\/11.4.515","article-title":"Infections due to Xylohypha bantiana (Cladosporium trichoides)","volume":"11","author":"Dixon","year":"1989","journal-title":"Clin Infect Dis."},{"key":"2021020323553600000_bib34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1128\/AAC.49.5.1701-1707.2005","article-title":"Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana","volume":"49","author":"Al-Abdely","year":"2005","journal-title":"AAC."},{"key":"2021020323553600000_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1439-0507.1987.tb03970.x","article-title":"Comparative histopathology of Dactylaria constricta, Fonsecaea pedrosoi, Wangiella dermatitidis, and Xylohypha bantiana in experimental phaeohyphomycosis of the central nervous system","volume":"30","author":"Walsh","year":"2009","journal-title":"Mykosen."}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/2\/189\/36087240\/myaa102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/2\/189\/36087240\/myaa102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T10:28:04Z","timestamp":1612780084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/59\/2\/189\/6031678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,12]]},"published-print":{"date-parts":[[2021,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myaa102","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,12,12]]}}}